Cancers are known to increase the tendency for thrombosis, both on the venous and arterial side, which to this day is an important factor in the management of oncology patients. Malignant disease is an independent risk factor for developing venous thromboembolism (VTE). Thromboembolic complications in addition to the disease worsen prognosis and are accompanied by significant morbidity and mortality. VTE is the second most common cause of death in cancer after disease progression. Tumors are characterized by hypercoagulability, in addition to which venous stasis and endothelial damage also occur in cancer patients promoting increased clotting. Treatment of cancer-associated thrombosis is often complex; therefore, it is important to identify patients who benefit from primary thromboprophylaxis. The importance of cancer-associated thrombosis is indisputable in everyday oncology. We briefly summarize the frequency and characteristics of their occurrence, the underlying mechanisms, risk factors, clinical appearance, laboratory diagnostics, and the possibilities of prevention and treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Rise and Fall of C-Reactive Protein: Can it Predict Immune Checkpoint Inhibitor-Associated Venous Thromboembolism?
JACC CardioOncol
December 2024
Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Net Clinical Benefit of 12-Month Over 3-Month Edoxaban in Cancer-Associated Isolated Distal Deep Vein Thrombosis.
JACC CardioOncol
December 2024
Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan.
Circulating tumor DNA: the dawn of new, clinically scalable biomarkers for thromboembolism.
J Thromb Haemost
January 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center. Electronic address:
Chemotherapy alters thrombomodulin and factor VIIIc expression resulting in acquired activated protein C resistance and enhanced thrombin generation in cancer associated thrombosis.
Thromb Res
December 2024
Department of Obstetrics and Gynaecology, Trinity College Dublin, Dublin, Ireland; Trinity St. James's Cancer Institute, Dublin, Ireland. Electronic address:
Background: Tumour type, treatment and patient related factors contribute to cancer associated venous thromboembolism (VTE), however, the role of each factor and the mechanisms involved are not understood.
Aim: To assess the role of the tumour, and of chemotherapy, in mediating the procoagulant response associated with VTE in gynaecological cancer patients.
Methods: Gynaecological cancer patients who developed VTE during follow-up (n = 59) (VTE+) were matched with treatment naïve(treatment (-)(VTE-)(n = 120) and chemotherapy treated patients(treatment (+)(VTE-) (n = 57)).
A mouse model of deep vein thrombosis by inferior vena cava hypoperfusion using ameroid constrictors.
Sci Rep
January 2025
Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Kanagawa, Japan.
Traditional mouse models for deep vein thrombosis (DVT), frequently utilized in research focused on cancer-associated thrombosis (CAT), reliably induce thrombus formation by obstructing blood flow (BF) in the inferior vena cava (IVC), which does not occur in humans. Therefore, to develop a new DVT model for CAT studies, we implanted an ameroid constrictor (AC), a hygroscopic casein C-shape device, around the IVC and aorta of immunocompromised mice. We evaluated the thrombus 3 and 8 days post-AC implantation and compared it with the traditional model 2 days post-vena cava ligation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!